Halliday BP, Owen R, Gregson J, et al. - Researchers sought to characterize adverse ventricular remodelling following therapy withdrawal in recovered dilated cardiomyopathy (DCM). The safety as well as the feasibility of therapy withdrawal was assessed in patients with recovered DCM over 6 months in the TRED‐HF, a randomised controlled trial with a follow‐on single arm cross‐over phase. Relapse of heart failure was the primary endpoint. In the randomised comparison, withdrawing therapy resulted in an increment in mean left ventricular (LV) mass as well as cell mass and a decrease in LV and right ventricular global longitudinal strain (GLS). Experts noted an increase in LV mass, cell mass and matrix mass as well as a decrease in LV GLS in a non‐randomised comparison of all patients (n = 47) who had therapy withdrawn in either phase. Similar changes were exhibited by those who had therapy withdrawn and did not relapse. According to findings from TRED‐HF, withdrawing therapy resulted in rapid remodelling, with early tissue as well as functional alterations, even in cases with no relapse.